KR102832376B1 - 암의 치료를 위한 tgf-베타 r1(alk5) 억제제로서의(피리딘-2-일)아민 유도체 - Google Patents
암의 치료를 위한 tgf-베타 r1(alk5) 억제제로서의(피리딘-2-일)아민 유도체 Download PDFInfo
- Publication number
- KR102832376B1 KR102832376B1 KR1020217021785A KR20217021785A KR102832376B1 KR 102832376 B1 KR102832376 B1 KR 102832376B1 KR 1020217021785 A KR1020217021785 A KR 1020217021785A KR 20217021785 A KR20217021785 A KR 20217021785A KR 102832376 B1 KR102832376 B1 KR 102832376B1
- Authority
- KR
- South Korea
- Prior art keywords
- mixture
- compound
- delete delete
- stirred
- etoac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785616P | 2018-12-27 | 2018-12-27 | |
| US62/785,616 | 2018-12-27 | ||
| PCT/US2019/066993 WO2020139636A1 (en) | 2018-12-27 | 2019-12-17 | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210110316A KR20210110316A (ko) | 2021-09-07 |
| KR102832376B1 true KR102832376B1 (ko) | 2025-07-09 |
Family
ID=69185691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217021785A Active KR102832376B1 (ko) | 2018-12-27 | 2019-12-17 | 암의 치료를 위한 tgf-베타 r1(alk5) 억제제로서의(피리딘-2-일)아민 유도체 |
Country Status (16)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021216454A1 (en) | 2020-04-21 | 2021-10-28 | Lexicon Pharmaceuticals, Inc. | 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections |
| JP2023522688A (ja) | 2020-04-21 | 2023-05-31 | レクシコン ファーマシューティカルズ インコーポレイテッド | ウイルス感染症の治療に使用されるａａｋ１阻害剤 |
| CN113214111A (zh) * | 2021-04-30 | 2021-08-06 | 上海立科化学科技有限公司 | 3-（2-氰基苯基）丙酸及4-氰基-1-茚满酮的制备方法 |
| US12263576B2 (en) | 2021-08-19 | 2025-04-01 | Hyundai Mobis Co., Ltd. | Robot system for automated assembly of modular component |
| EP4464694A4 (en) * | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN121554469B (zh) * | 2026-01-23 | 2026-04-17 | 四川大学华西医院 | 一种alk5 protac化合物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009022171A1 (en) | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| WO2016057278A1 (en) | 2014-10-07 | 2016-04-14 | Eli Lilly And Company | Aminopyridyloxypyrazole compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1397364T1 (sl) | 2001-05-24 | 2007-12-31 | Lilly Co Eli | Novi pirolni derivati kot farmacevtske uäśinkovine |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| WO2012151137A1 (en) * | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
| WO2014048065A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| EP2934525B1 (en) * | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| WO2014155300A2 (en) * | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Substitued pyrimidine amine derivatives as tak-1 inhibitors |
| PL3089971T3 (pl) * | 2014-01-01 | 2021-01-25 | Medivation Technologies Llc | Związki i sposoby ich zastosowania |
| JP6767875B2 (ja) | 2014-04-08 | 2020-10-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｔｇｆ−ベータ阻害剤としての２，３−二置換ピリジン化合物および使用方法 |
| CA2986441A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN108026105B (zh) | 2015-07-23 | 2020-10-16 | 百时美施贵宝公司 | TGFβ受体拮抗剂 |
| WO2020103817A1 (zh) | 2018-11-20 | 2020-05-28 | 南京圣和药业股份有限公司 | TGF-βR1抑制剂及其应用 |
| KR102816656B1 (ko) | 2019-06-25 | 2025-06-02 | 인벤티스바이오 컴퍼니 리미티드 | 헤테로고리 화합물, 이의 제조방법 및 이의 사용방법 |
| CN112707902B (zh) | 2020-03-23 | 2022-04-15 | 杭州阿诺生物医药科技有限公司 | TGF-β受体抑制剂 |
-
2019
- 2019-12-17 SG SG11202103457PA patent/SG11202103457PA/en unknown
- 2019-12-17 MX MX2021007738A patent/MX2021007738A/es unknown
- 2019-12-17 ES ES19839715T patent/ES2972516T3/es active Active
- 2019-12-17 AU AU2019417418A patent/AU2019417418B2/en active Active
- 2019-12-17 CA CA3117838A patent/CA3117838A1/en active Pending
- 2019-12-17 WO PCT/US2019/066993 patent/WO2020139636A1/en not_active Ceased
- 2019-12-17 US US17/299,696 patent/US12102626B2/en active Active
- 2019-12-17 EA EA202191619A patent/EA202191619A1/ru unknown
- 2019-12-17 KR KR1020217021785A patent/KR102832376B1/ko active Active
- 2019-12-17 EP EP19839715.0A patent/EP3902796B1/en active Active
- 2019-12-17 IL IL284266A patent/IL284266B2/en unknown
- 2019-12-17 BR BR112021007006-0A patent/BR112021007006A2/pt unknown
- 2019-12-17 JP JP2021536757A patent/JP7515049B2/ja active Active
- 2019-12-17 CN CN201980086920.0A patent/CN113348167B/zh active Active
- 2019-12-25 TW TW108147526A patent/TWI884934B/zh active
- 2019-12-27 AR ARP190103894A patent/AR117539A1/es unknown
-
2023
- 2023-01-17 JP JP2023005014A patent/JP2023052437A/ja active Pending
-
2024
- 2024-08-05 US US18/795,000 patent/US20240398776A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009022171A1 (en) | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| WO2016057278A1 (en) | 2014-10-07 | 2016-04-14 | Eli Lilly And Company | Aminopyridyloxypyrazole compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113348167A (zh) | 2021-09-03 |
| TW202039436A (zh) | 2020-11-01 |
| IL284266B1 (en) | 2024-02-01 |
| AR117539A1 (es) | 2021-08-11 |
| BR112021007006A2 (pt) | 2021-08-10 |
| IL284266B2 (en) | 2024-06-01 |
| KR20210110316A (ko) | 2021-09-07 |
| WO2020139636A1 (en) | 2020-07-02 |
| TWI884934B (zh) | 2025-06-01 |
| AU2019417418A1 (en) | 2021-04-15 |
| EP3902796A1 (en) | 2021-11-03 |
| CN113348167B (zh) | 2026-01-09 |
| NZ775362A (en) | 2025-02-28 |
| US20240398776A1 (en) | 2024-12-05 |
| EA202191619A1 (ru) | 2021-09-28 |
| IL284266A (en) | 2021-08-31 |
| CA3117838A1 (en) | 2020-07-02 |
| EP3902796C0 (en) | 2024-02-07 |
| ES2972516T3 (es) | 2024-06-13 |
| US12102626B2 (en) | 2024-10-01 |
| JP2022517730A (ja) | 2022-03-10 |
| EP3902796B1 (en) | 2024-02-07 |
| SG11202103457PA (en) | 2021-05-28 |
| JP2023052437A (ja) | 2023-04-11 |
| AU2019417418B2 (en) | 2025-02-27 |
| JP7515049B2 (ja) | 2024-07-12 |
| MX2021007738A (es) | 2021-08-05 |
| US20220054465A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7515049B2 (ja) | がんの処置のためのｔｇｆ－ベータｒ１（ａｌｋ５）阻害剤としての（ピリジン－２－イル）アミン誘導体 | |
| KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
| US11795172B2 (en) | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | |
| US12162863B2 (en) | Modulators of stimulator of interferon genes (STING) | |
| JP6137193B2 (ja) | 第ＸＩａ因子阻害剤としての新規ピリジノンおよびピリミジノン誘導体 | |
| ES2463676T3 (es) | Inhibidor de la producción de quinurenina | |
| KR102609431B1 (ko) | Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체 | |
| JP2021506735A (ja) | 新規ｍａｐ４ｋ１阻害剤 | |
| CN107922386B (zh) | 1,4-二取代的咪唑衍生物 | |
| CN104744446A (zh) | 杂芳化合物及其在药物中的应用 | |
| TW202426440A (zh) | 一種蛋白酪胺酸激酶抑制劑及其醫藥用途 | |
| HK40063493B (en) | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | |
| HK40063493A (en) | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | |
| EA043088B1 (ru) | Производные (пиридин-2-ил)амина в качестве ингибиторов tgf-бета r1 (alk5) для лечения злокачественных новообразований | |
| KR102655210B1 (ko) | 아데노신 a2a 수용체 길항제 및 이의 용도 | |
| WO2025215153A1 (en) | Prmt5 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |